Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
NNX 0.035 +0.0% ABX 51.92 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.70 +9.1% TUNG 1.74 +3.0% LGO 1.00 −3.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.49 +0.9% SGZ 0.045 +0.0% S 0.160 +33.3% GRSL 0.305 −4.7% DEX 0.390 +1.3% WMS 0.040 +0.0% NNX 0.035 +0.0% ABX 51.92 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.70 +9.1% TUNG 1.74 +3.0% LGO 1.00 −3.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.49 +0.9% SGZ 0.045 +0.0% S 0.160 +33.3% GRSL 0.305 −4.7% DEX 0.390 +1.3% WMS 0.040 +0.0%
None

SEDAR Interim Financial Statements

By The Northwire Desk — AI Analysis Nov 27, 2025 · 17:37 ZCT · 0.2 Zero Candida Technologies Inc
ZCT · Price

[ { "companyName": "Zero Candida Technologies Inc.", "reportingPeriodEnd": "2025-09-30", "reportStatus": "Unaudited", "auditorName": null, "auditorKeyMatters": [], "balanceSheet": { "cash": 281, "totalCurrentAssets": null, "totalCurrentLiabilities": null, "totalAssets": null, "totalLiabilities": null, "totalEquity": null, "derivedMetrics": { "cashPerShare": 0.0144, "workingCapitalPerShare": null } }, "incomeStatement": { "revenue": null, "costOfSales": null, "grossProfit": null, "operatingExpenses": null, "operatingLoss": null, "netLoss": null, "basicLossPerShare": null, "weightedAverageSharesOutstanding": 19533037 }, "cashFlowStatement": { "cashFromOperatingActivities": null, "cashFromInvestingActivities": null, "cashFromFinancingActivities": null, "netChangeInCash": null, "cashAtBeginningOfPeriod": null, "cashAtEndOfPeriod": 281 }, "investmentsAndOtherAssets": [ { "type": "Subsidiary", "description": "Zero Candida Ltd., Israel", "ownershipPercentage": 100, "value": null, "notes": "Controlled subsidiary, functional currency NIS" } ], "shareStructure": { "authorizedShares": "19,533,037", "issuedShares": 19533037, "classesOfShares": ["common shares"], "warrants": [], "options": [ { "number": 560000, "exercisePrice": 0.25, "expiryDate": null } ], "rightsConvertibleInstruments": null }, "managementCompensation": { "currency": "CAD", "periods": null, "namedIndividuals": [], "otherRelatedPartyTransactions": [ { "counterparty": "Key Management Personnel", "description": "Deferred consulting fees included in accounts payable", "amount": 879, "period": "As at September 30, 2025" } ] }, "subsequentEvents": [] } ]

Read the original news release →

More from Zero Candida Technologies Inc

Jun 24, 2026 · 08:00

Zero Candida announced officially been granted Patent No. 12654025B2 -- a meaningful milestone that reflects our commitment to innovation, technology, and long-term impact

Other Feb 17, 2026 · 08:00

Zero Candida Scales Production to 250 ISO 13485 Clinical-Grade Prototypes of ZC-001 Therapeutic Device

Production / Operations Oct 20, 2025 · 09:00

Zero Candida Achieves Design Freeze and Begins Prototype Production of ZC-001 Therapeutic Device

Production / Operations